BeiGene (6160.HK/BGNE.US/688235.CH) - 2023 Results Preview and Undervaluation Concerns
⬆ $BeiGene (06160)$ - BeiGene's sluggish share price could be related to geopolitical conflicts/weak market sentiment. But there’s no need for US to sanction China's biotech. We're optimistic about BeiGene's 2023 results.
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/beigene-6160-hk-bgne-us-688235-ch-2023-results-preview-and-undervaluation-concerns?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On BeiGene (06160):- https://www.smartkarma.com/entities/beigene-ltd?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
